For research use only. Not for therapeutic Use.
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD)[1].
The simultaneous binding of Ordesekimab (AMG 714) to the Fcγ receptor (R) IIIα expressed on natural killer (NK) cells and to the IL-15/IL-15Rα complex on cells such as monocytes may theoretically enable antibody-dependent cell-mediated cytotoxicity (ADCC) toward the IL-15Rα-expressing cells[1].
| Catalog Number | I042398 |
| CAS Number | 879293-15-9 |
| Purity | ≥95% |
| Reference | [1]. Yu-Ling Wei, et al. Strategies to evaluate potential effector function of glycan variants: a case study of ordesekimab (AMG 714 or PRV-015). J Immunotoxicol. 2022 Dec;19(1):109-116. |
